Show simple item record

dc.contributor.authorPatel, K
dc.contributor.authorForetz, M
dc.contributor.authorMarion, A
dc.contributor.authorCampbell, DG
dc.contributor.authorGourlay, R
dc.contributor.authorBoudaba, N
dc.contributor.authorTournier, E
dc.contributor.authorTitchenell, P
dc.contributor.authorPeggie, M
dc.contributor.authorDeak, M
dc.contributor.authorWan, M
dc.contributor.authorKaestner, KH
dc.contributor.authorGöransson, O
dc.contributor.authorViollet, B
dc.contributor.authorGray, NS
dc.contributor.authorBirnbaum, MJ
dc.contributor.authorSutherland, C
dc.contributor.authorSakamoto, K
dc.date.accessioned2017-11-08T14:43:26Z
dc.date.issued2014-08-04
dc.description.abstractLKB1 is a master kinase that regulates metabolism and growth through adenosine monophosphate-activated protein kinase (AMPK) and 12 other closely related kinases. Liver-specific ablation of LKB1 causes increased glucose production in hepatocytes in vitro and hyperglycaemia in fasting mice in vivo. Here we report that the salt-inducible kinases (SIK1, 2 and 3), members of the AMPK-related kinase family, play a key role as gluconeogenic suppressors downstream of LKB1 in the liver. The selective SIK inhibitor HG-9-91-01 promotes dephosphorylation of transcriptional co-activators CRTC2/3 resulting in enhanced gluconeogenic gene expression and glucose production in hepatocytes, an effect that is abolished when an HG-9-91-01-insensitive mutant SIK is introduced or LKB1 is ablated. Although SIK2 was proposed as a key regulator of insulin-mediated suppression of gluconeogenesis, we provide genetic evidence that liver-specific ablation of SIK2 alone has no effect on gluconeogenesis and insulin does not modulate SIK2 phosphorylation or activity. Collectively, we demonstrate that the LKB1-SIK pathway functions as a key gluconeogenic gatekeeper in the liver.en_GB
dc.description.sponsorshipThis work was supported by the British MRC, the Re´gion Ile-de-France (CORDDIM), Socie´te´ Francophone du Diabe´te (SFD) and the pharmaceutical companies supporting the Division of Signal Transduction Therapy Unit (AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck KgaA, Janssen Pharmaceutica and Pfizer). K.P. is supported by the Wellcome Trust PhD Programme for Clinicians (093991/Z/10/Z) and A.M. is a recipient of a post-doctoral fellowship from the Re´gion Ile-de-France (CORDDIM). This work is supported by the NIH Grant RO1DK56886 to M.J.B.en_GB
dc.identifier.citationVol. 5, article 4535en_GB
dc.identifier.doi10.1038/ncomms5535
dc.identifier.urihttp://hdl.handle.net/10871/30210
dc.language.isoenen_GB
dc.publisherSpringer Natureen_GB
dc.relation.sourceThe mass spectrometry data has been deposited to the ProteomeXchange Consortium40 via the PRIDE partner repository under the accession code PXD001032.en_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/25088745en_GB
dc.rightsOpen access. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/en_GB
dc.subjectAnimalsen_GB
dc.subjectFastingen_GB
dc.subjectGene Expression Regulationen_GB
dc.subjectGlucagonen_GB
dc.subjectGluconeogenesisen_GB
dc.subjectGlucoseen_GB
dc.subjectHepatocytesen_GB
dc.subjectHyperglycemiaen_GB
dc.subjectInsulinen_GB
dc.subjectLiveren_GB
dc.subjectMaleen_GB
dc.subjectMiceen_GB
dc.subjectMice, Knockouten_GB
dc.subjectPhenylurea Compoundsen_GB
dc.subjectPhosphorylationen_GB
dc.subjectProtein Kinase Inhibitorsen_GB
dc.subjectProtein-Serine-Threonine Kinasesen_GB
dc.subjectPyrimidinesen_GB
dc.subjectSignal Transductionen_GB
dc.subjectTranscription Factorsen_GB
dc.titleThe LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liveren_GB
dc.typeArticleen_GB
dc.date.available2017-11-08T14:43:26Z
exeter.place-of-publicationEnglanden_GB
dc.descriptionThis is the final version of the article. Available from Springer Nature via the DOI in this record.en_GB
dc.identifier.journalNature Communicationsen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record